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of disease-associated BDNF alterations. Their identification 
as either state or trait marker remains controversial and re-
quires larger-scale longitudinal studies.
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 Introduction
 Brain-derived neurotrophic factor (BDNF) is involved 
in the promotion of neuronal growth, the maintenance of 
synaptic functioning and neural plasticity as well as neu-
ronal repair and survival  [1, 2] . The ‘neurotrophin hy-
pothesis’ of depression postulates a stress-induced or 
stress-associated BDNF decrease as a pivotal pathomech-
anism of affective disorders such as major depressive dis-
order (MDD) or bipolar disorder  [3–5] . Both antidepres-
sant medication and electroconvulsive therapy (ECT) in-
duce an increase in both central and peripheral BDNF 
levels, suggesting that the amelioration of depressive 
symptoms in the wake of these therapeutic regimens is at 
least partly modulated by BDNF  [6–8] . Direct delivery of 
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 Abstract
 Introduction: According to the neurotrophin hypothesis, a 
brain-derived neurotrophic factor (BDNF) decrease has been 
postulated as a pivotal pathomechanism in affective disor-
der, and the treatment-associated increase in peripheral 
BDNF has been linked to therapeutic efficacy of antidepres-
sant drugs and electroconvulsive therapy. However, in deep 
brain stimulation (DBS), a still experimental antidepressant 
treatment approach, this issue has not yet been investigated. 
 Methods: We examine the long-term course of serum BDNF 
levels in a 64-year-old woman who is being treated with DBS 
of the lateral habenula for severe major depressive disorder. 
 Results: Our main findings are a significant increase in BDNF 
serum levels following DBS of the lateral habenula and an 
inverse U-shaped correlation of depression scores and BDNF 
levels.  Discussion: The data indicate that DBS, like other ef-
fective antidepressant treatments, may contribute to an in-
crease in peripheral BDNF levels, which are thought to re-
flect central nervous DBS-induced neuroplastic changes. 
Moreover, our observations underscore the complex nature 
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BDNF into the hippocampus of rats  [9–11] and mice  [12] 
has shown an antidepressant effect in animal models of 
depression; these effects in turn were blocked when a 
forebrain-specific knockout of the BDNF-encoding gene 
was performed  [13] . Thus, it seems tempting to employ 
the serum BDNF level as an easily accessible biomarker 
indicating a state of affective imbalance or, more gener-
ally, stress  [14, 15] . However, the straightforward mea-
surement and interpretation of serum BDNF is impeded 
by several factors: (1) platelets are known to store BDNF 
and are able to release it in response to certain triggers 
 [16] ; (2) the serum BDNF concentration is up to 50-fold 
higher than the plasma concentration, thus serum levels 
basically reflect the platelet depot  [17] ; (3) it is uncertain 
whether the peripherally measured levels truly represent 
the central status. However, it has been demonstrated in 
preclinical studies that central and peripheral levels cor-
relate in a sufficient way, but with a time delay of the mag-
nitude of a platelet’s lifespan  [18–20] .
 The recent adoption of deep brain stimulation (DBS) 
for psychiatric disease such as obsessive-compulsive dis-
order, Tourette’s syndrome or major depression has al-
ready shown efficacy in a well-chosen, highly treatment-
resistant collective  [21–23] . While clinical results for pa-
tients suffering from chronic MDD are promising, the 
currently still experimental nature of DBS calls for a com-
prehensive analysis of mechanisms alongside the evalua-
tion of antidepressant efficacy. So far, the question wheth-
er DBS may influence BDNF levels has not yet been in-
vestigated. Since increased BDNF expression has been 
found in the wake of ECT or treatment with antidepres-
sant medication, both in preclinical and clinical studies, 
we assume that DBS – if effective in treatment-resistant 
major depression – will also lead to an increase in BDNF. 
Here we provide case data from a female patient with ma-
jor depression who received DBS of the lateral habenula, 
a new target for DBS  [24] .
 Methods
 The case has been described in greater detail elsewhere  [25] . In 
brief, a 64-year-old female patient had been suffering from major 
depressive episodes since the age of 18 without any signs of bipo-
larity. Appropriate pharmacotherapy including antidepressants 
of different modes of action, as well as combination and augmen-
tation strategies, could not control the illness. At the age of 59 she 
received ECT for the first time. Although remission was achieved, 
it was not stable. During maintenance ECT, which was initiated 
after several relapses, it was impossible to extend between-session 
intervals to more than 2 weeks without relapse despite concomi-
tant medication. With deteriorating quality of life and increasing 
ECT- and pharmacotherapy-associated side effects, DBS surgery 
was performed in July 2008 in order to dampen an assumed over-
activation of the lateral habenula, which, through its reciprocal 
connections with dopaminergic and serotonergic neurons, has 
been implicated in the pathophysiology of depression  [26, 27] . 
DBS treatment resulted in a sustained full remission of depressive 
symptoms in our severely ill patient. Interestingly, she suffered 
from a relapse when stimulation was accidentally discontinued 
( fig. 1 ). In the 60 weeks following surgery, the patient was closely 
monitored every other week. Due to the severity of the illness, she 
received psychotropic medication during the observation period. 
She received risperidone, sertraline and mirtazapine at stable dos-
es. During week 16, clinical management necessitated a switch 
from sertraline to venlafaxine and the re-introduction of lithium 
during week 17. From that time onwards, medication remained 
unchanged. During the biweekly visits, we performed clinical ex-


































 Fig. 1. Longitudinal course of the patient’s HAM-D scores ( d ) 
and corresponding serum BDNF levels ( S ). 
 Fig. 2. Regression analysis depicting the correlation between 
HAM-D scores and serum BDNF. 
 BDNF Serum Levels after DBS of the 
Lateral Habenula 
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pression (HAM-D) as well as BDNF serum level measurement. 
The time course of BDNF serum levels and symptom severity 
measured by the HAM-D is displayed in  figure 1 . In  figure 2 we 
show BDNF levels in relation with HAM-D scores.
 Method of Serum BDNF Measurement and
Statistical Analysis
 Samples of venous blood were taken in additive-free serum 
containers and were left to clot for about 1 h, followed by centrif-
ugation at 4,000 rpm for 4 min at room temperature. Serum sam-
ples were stored at –80   °   C until analysis. BDNF levels in serum 
were quantified as described in detail earlier  [28] . The neuro-
trophin levels were expressed as nanograms per millilitre. Special 
care was taken to minimize the influence of unavoidable vari-
ances between experiments  [29] . Regression analysis and t tests 
were performed using Stata  (Stata Corp, Tex., USA, version 11) 
at a significance level of 0.05.
 Results
 Initially Lower BDNF Levels
 As it can be seen in  figure 1 , an obvious step of BDNF 
levels can be detected after week 13 (DBS started at week 
1). The mean of all measured BDNF levels until week 13 
is 5.8  8 2.0 ng/ml, the mean of all BDNF levels later on 
8.2  8 2.2 ng/ml. This increase is significant, even if only 
weeks 0–13 and weeks 14–45 are compared (p = 0.0001 
vs. p = 0.001, respectively, for a two-sided t test). BDNF 
levels taken from 9 weeks to 3 weeks  before DBS surgery 
had been even lower, i.e. 3.7  8 1.7 ng/ml (n = 6 measure-
ments).
 Inverse U-Shaped Correlation of HAM-D and BDNF 
Serum Levels
 As can be seen in  figure 2 , an inverse U-shaped cor-
relation of HAM-D and BDNF can be derived from our 
data. To model an inverse U-shaped relation, we used the 
simplest mathematical assumption, which is a second-
order polynomial regression. A regression analysis (as 
shown in  fig. 2 ) yields a significant correlation at p = 0.035 
(n = 23, r 2  = 0.21). Since we also detected a linear correla-
tion between BDNF serum levels and thrombocytes per 
nanolitre, we included platelet count as a covariate into 
the regression analysis. The covariate influence was not 
significant, however (p = 0.12).
 Discussion
 Here we describe for the first time long-term changes 
in BDNF serum levels in a patient who had undergone 
DBS of the lateral habenula for treatment-resistant MDD. 
Our data corroborate findings of serum BDNF increase 
under efficient antidepressive treatments such as antide-
pressant pharmacotherapy and ECT  [14, 30] . While we 
are unaware of studies investigating the course of BDNF 
in the wake of DBS treatment for depression in a system-
atic way, it was previously shown that the antidepressant 
effect observed after programmed acute electrical stimu-
lation of the ventral tegmental area in a rat genetic mod-
el of depression was accompanied by increases in BDNF 
mRNA and protein levels in the prefrontal cortex and the 
nucleus accumbens  [31] . Furthermore, the temporally 
shifted correlation with symptom severity in this study is 
in line with the idea that a time lag of necessity exists for 
central BDNF to come to an equilibrium with peripheral 
BDNF levels in the platelet pool, as suggested previously 
by a systematic time course of central and peripheral 
BDNF levels after chronic ECT in rats  [20] . Similarly, sig-
nificant increases in serum BDNF levels were found in 
ECT-treated patients 1 month after cessation of the pro-
cedure while no changes had been noted immediately af-
ter the last session  [32] . Thus, the central BDNF level 
change presumably happens first, followed by a relatively 
fast improvement of psychopathology and a delayed in-
crease in peripheral BDNF levels  [20] . Finally, neurons of 
the lateral habenula project to the ventral tegmental area 
and the dorsal raphe nuclei, which are critically involved 
in the release of dopamine and serotonin, respectively 
 [26, 27] . Since serotonin impacts on BDNF expression 
and genetic epistasis of the two systems has been ob-
served in different species  [33] , habenular functional 
modulation through DBS may thus indirectly influence 
BDNF.
 While the BDNF elevation certainly cannot be exclu-
sively attributed to DBS action in our case, the observed 
time lag nonetheless supports the notion that DBS con-
tributed to BDNF level alterations. In addition, the long 
and severe disease history renders placebo response  [34] 
or natural remission rather unlikely.
 The low peripheral BDNF our patient presented with 
immediately prior to DBS, when severe symptoms were 
present, would argue for BDNF decrease as a state mark-
er for depression. The observed rise of serum BDNF un-
der efficient antidepressant treatment would also be in 
accordance with this. However, levels did not remain sta-
bly elevated but even though the patient reached a sus-
tained formal remission, serum BDNF returned to lower 
levels. Given the long psychiatric history of our patient, 
there is certainly a high intrinsic vulnerability for MDD. 
Along these lines, low peripheral BDNF is apparently not 
limited to phases of acute disease but has also been ob-
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served in euthymic MDD or bipolar disorder patients  [35] 
as well as bipolar mania  [36] , in healthy subjects with de-
pression-related personality traits  [37] and bipolar disor-
der patients with adverse childhood experiences  [38] . The 
identification of the nature of low BDNF levels as either 
a state marker or an endophenotypic trait is thus not 
straightforward. According to Kapczinski et al.  [39] , the 
pattern of BDNF levels in patients with mood disorders 
should be interpreted ‘as a composite of changes related 
to the  trait of having a mood disorder and  state changes 
related to the strain imposed by environmental factors 
and repeated mood episodes’. We share this view in the 
sense that the depressive trait obviously goes along with 
lower BDNF levels and any kind of sufficient antidepres-
sive action raises these levels, resulting in a temporarily 
delimited BDNF increase, which might thus be required 
for an antidepressive effect. After this transient increase, 
BDNF levels then return back to or almost to trait level. 
The inverse U-shaped relation between symptom severity 
and BDNF levels from our patient is in line with this view. 
Alternatively, disease episode-bound BDNF decreases – 
here one would assume BDNF to be a true state mark -
 er – may occur repeatedly over a long period of time and 
lead to dysregulation and lasting imbalance of the system 
so that a recovery to normal values does not occur (for a 
recent study invoking an explanation along these lines for 
decreased BDNF levels in patients in early remission, see 
Molendijk et al.  [40] ). In general, there is a paucity of 
studies investigating long-term BDNF changes in pa-
tients suffering from affective disorders.
 Interpretations of peripheral BDNF, its exact role, rel-
evance and implications for disease pathophysiology cru-
cially rest on the assumption of serum BDNF truly re-
flecting cerebral BDNF metabolism. There is substantial 
evidence in favour of this assumption  [18–20, 41, 42] ; nev-
ertheless, there are a number of important aspects to con-
sider, the first of which concerns blood-brain barrier per-
meability of BDNF. Findings are equivocal with regard to 
this question  [43] . Second, both peripherally and central-
ly, mononuclear cells and T cells contribute to BDNF pro-
duction constitutively as well as upon certain activation 
signals  [44, 45] . Inflammatory processes have been im-
plied in depression pathophysiology  [46] , and as they are 
intimately linked to mononuclear, T and B cell activity, 
changes of BDNF levels in depression may result from 
altered immune cell activitiy. Third, neurons, the prima-
ry source of BDNF in the central nervous system  [47] , 
possess distinct mechanisms allowing for a rapid and dy-
namic regulation of BDNF expression, localization and 
synaptic delivery  [48] . Thus, further characterization of 
these mechanisms, the ways in which they are potential-
ly impaired in affective disorder and how that may affect 
peripheral BDNF levels may shed further light upon the 
relation between central and peripheral states. Decreased 
peripheral BDNF levels might also result from dysregu-
lated BDNF expression or release by peripheral cells  [49] , 
particularly platelets, the function of which has been 
shown to be altered in depression  [50, 51] . While we ob-
served a correlation between platelet counts and BDNF 
levels in our patient, platelet count did not significantly 
influence our results. A similar correlation, not con-
founded by the co-occurrence of a psychiatric disorder 
such as depression or dementia, was previously found in 
a sample of elderly individuals  [28] . Last but not least, glu-
cocorticoids inhibit BDNF production  [52] , and hyper-
cortisolism in depression may accordingly contribute to 
a disease-associated decrease in BDNF. We are well aware 
of the inherent limitations of a case study like the one 
presented here, most prominently its retrospective and 
descriptive character, whereby it lacks experimental con-
trol, and issues of generalizability. However, case obser-
vations are a valuable means of generating hypotheses 
and collecting information. This is especially relevant 
with regard to as yet experimental therapeutic methods 
such as DBS for the treatment of affective disorders, for 
which there is still limited clinical experience  [23] and 
currently only one follow-up study  [22] .
 In summary, this is the first case of a patient suffering 
from MDD with longitudinal alterations of BDNF under 
concurrent DBS. Beyond the impressive clinical outcome 
of the patient, the course of BDNF levels also supports our 
hypothesis that stimulating the habenula could lead to 
amelioration of symptoms in patients suffering from 
treatment-resistant severe MDD. In this sense, antide-
pressive treatment – habenular DBS in our case – may 
induce neuroplastic changes that are indexed to serum 
BDNF. Changes in BDNF may even serve as a treatment 
response marker because the absence of an early increase 
in peripheral BDNF has been shown to predict non-re-
sponse to antidepressant therapy  [53] . The measurement 
of serum BDNF levels following the course of illness for 
a considerable time during all phases of the disease is cer-
tainly an important prerequisite to further elucidate the 
role of BDNF in affective disorder and gain insight into 
mechanisms of effective antidepressant treatment op-
tions.
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